首页> 美国卫生研究院文献>Journal of Virology >Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay
【2h】

Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay

机译:在体外竞争性HIV-1复制检测中抗多脱氧核苷的人类免疫缺陷病毒1型(HIV-1)的比较适应性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

We examined whether human immunodeficiency virus type 1 (HIV-1) fitness was altered upon the acquisition of a set or subset of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene, which confers resistance to multiple dideoxynucleosides (MDR), as well as the zidovudine resistance-associated mutation T215Y, using a competitive HIV-1 replication assay in a setting of an HXB2D genetic background. Target H9 cells were exposed to a 50:50 mixture of paired infectious molecular clones, and HIV-1 in the culture supernatant was transmitted to new cultures every 7 to 10 days. The polymerase-encoding region of the virus was sequenced at various time points, and the relative proportion of the two viral populations was determined. In the absence of drugs, the comparative order for replicative fitness was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > wild-type HIV-1 (HIV-1wt) > HIV-175/77/116/151 > HIV-1151/215 > HIV-1215. In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-175/77/116/151 > HIV-1151 > HIV-1215. HIV-1215S(TCC), a putative intermediate infectious clone for HIV-1215, replicated comparably to HIV-1wt, while two putative intermediates for HIV-1151 [HIV-1151L(CTG) and HIV-1151K(AAG)] replicated much less efficiently than HIV-1wt and HIV-1151, suggesting that for HIV-1151 to develop, two base substitutions are likely to occur concurrently or within a short interval. These data may illustrate the molecular basis by which HIV-1151 emerges much less frequently than HIV-1215. The present data also demonstrate that several MDR HIV-1 variants are more fit than HIV-1wt in the absence of drugs and that resistance-associated mutations and drug pressure are critical variates for HIV-1 fitness.
机译:我们检查了在pol基因中获得五个或多个突变(A62V,V75I,F77L,F116Y和Q151M)的突变集或子集后,人类1型免疫缺陷病毒(HIV-1)的适应性是否改变,这些突变赋予对多种双脱氧核苷的抗性(MDR)以及齐多夫定耐药相关突变T215Y,在HXB2D遗传背景下使用竞争性HIV-1复制测定法。将靶H9细胞暴露于50:50的成对传染性分子克隆混合物中,每7至10天将培养上清液中的HIV-1传播到新的培养物中。在不同时间点对病毒的聚合酶编码区进行测序,并确定了两个病毒种群的相对比例。在没有药物的情况下,复制适应性的相对顺序为HIV-162 / 75/77/116/151> HIV-177 / 116/151> HIV-1151>野生型HIV-1(HIV-1wt)> HIV -175/77/116/151> HIV-1151 / 215> HIV-1215。在齐多夫定或二羟肌苷存在下,顺序为HIV-162 / 75/77/116/151> HIV-177 / 116/151> HIV-175 / 77/116/151> HIV-1151> HIV-1215。 HIV-1215S(TCC)是HIV-1215的一种假定的中间传染性克隆,可与HIV-1wt相似地复制,而HIV-1151的两种假定的中间体[HIV-1 151L(CTG)和HIV- 1 151K(AAG)]的复制效率远低于HIV-1 wt 和HIV-1 151 ,这表明HIV-1 151 发展起来,两个碱基取代很可能同时发生或在很短的间隔内发生。这些数据可以说明HIV-1 151 出现的分子基础比HIV-1 215 少得多。目前的数据还表明,在没有药物的情况下,几种耐多药的HIV-1变异体比HIV-1 wt 更合适,而与耐药相关的突变和药物压力是HIV-1适应性的关键变异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号